| 3-D Model Of Esophageal Cancer Created
ScienceDaily (Nov. 21, 2007) A team of scientists led by Dr. Anil Rustgi (UPenn) presents an innovative new model of esophageal cancer, which holds great promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease. .
Cell phone films take center stage
Masked and demure, she speaks from the tiny screen of a cell phone like a thumb-size fairy forever trapped inside. "Welcome home," she says softly to the viewer. "Speak to me about anything." The minuscule video is among the works on display at a film festival that opened Dec. 7in Yokohama, featuring 48 movies - all shot on camera-equipped cell phones. Hazy and raw but urgently personal, these pocket-size statements on film, like Yuka Kojima's five-minute Thumb Girl, were selected from more than 400 entries in an international contest. .
BioJournal - Kalorama Market Research
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, Over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. In addition to the basic pathology and complications of tuberculosis, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (tuberculosis patient trends) and technology. .
VELCADE(R) (Bortezomib) For Injection Based Therapy Produced ...
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone (VAD). This study was conducted by the Intergroupe Francophone du Myelome (IFM) cooperative group and CHU Nantes and selected for an oral presentation at the American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Ga., December 8-11, 2007.
"The very high complete and near complete remission rate of 21 percent with this induction therapy significantly improved post-transplantation complete remission rates. This led to a decrease in patients requiring a second transplant," said Professor Jean-Luc Harousseau, M.D., Hospital Hotel- Dieu Nantes and Principal Investigator of the trial.
Great pay equals great teachers
TIM Costello, thank you for your words of wisdom. As the parent of a young disabled son, I was touched by your comments and appreciate your understanding of the desperate situation of so many carers. How I wish you were running for prime minister. Cara Scott, Ivanhoe The new Tampa? DEJA VU, anyone? Just before an election, 16 men, women and children have been rescued from their leaky, overloaded boat by the Australian navy. Will we, the people of Australia, see a replay of 2001 and the Tampa or have we recognised our responsibility towards people who leave their countries seeking asylum? What will be our response if Messrs Howard and Andrews once again order them off to indefinite detention on Nauru? And how will Labor respond? Will Mr Rudd and his immigration spokesman play "me-too" on this issue? Or will we see some true leadership and applaud as they take the plunge and show clearly that a Labor government will treat asylum seekers with greater humanity.
Amgen Announces Interim Results Of Aranesp(R) ''PREPARE'' Study In ...
Amgen, Inc. (NASDAQ: AMGN) announced that it had received interim results from the independent investigator-sponsored "PREPARE" study, an open-label, randomized, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 733 neoadjuvant breast cancer patients receiving dose-dense, dose-intense preoperative chemotherapy compared to a standard preoperative chemotherapy regimen.
Initiated in 2002, the PREPARE study was developed, conducted and analyzed by the independent German Gynecological Oncology Study Group (AGO) and the German Breast Group. It was designed to evaluate the effects of preoperative chemotherapy using a sequential dose-dense and dose-intensified regimen of epirubicin, paclitaxel, and CMF compared to preoperative sequential administration of epirubicin and cyclophosphamide followed by paclitaxel in patients with breast cancer, with respect to event-free and overall survival, with or without Aranesp to prevent anemia and to potentially augment the therapeutic effects of the chemotherapy regimens.
|
